To include your compound in the COVID-19 Resource Center, submit it here.

Momenta gains on Phase I data for anti-FCRN mAb

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) added $2.80 (19%) to $17.55 on Friday after

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE